Management trial proves effectiveness of repurposed medication for COVID-19 remedy

In simply six months, the world’s largest randomized management trial on COVID-19 therapeutics has generated conclusive proof on the effectiveness of repurposed medication for the remedy of COVID-19.

Interim outcomes from the Solidarity Therapeutics Trial, coordinated by the World Well being Group, point out that remdesivir, hydroxychloroquine, lopinavir/ritonavir and interferon regimens appeared to have little or no impact on 28-day mortality or the in-hospital course of COVID-19 amongst hospitalized sufferers.

The examine, which spans greater than 30 international locations, appeared on the results of those therapies on total mortality, initiation of air flow, and length of hospital keep in hospitalized sufferers. Different makes use of of the medication, for instance in remedy of sufferers in the neighborhood or for prevention, must be examined utilizing totally different trials.

The progress achieved by the Solidarity Therapeutics Trial reveals that giant worldwide trials are doable, even throughout a pandemic, and provide the promise of shortly and reliably answering crucial public well being questions regarding therapeutics.

The outcomes of the trial are below overview for publication in a medical journal and have been uploaded as preprint at medRxiv obtainable.

The worldwide platform of the Solidarity Trial is able to quickly consider promising new remedy choices, with almost 500 hospitals open as trial websites.

Newer antiviral medication, immunomodulators and anti-SARS COV-2 monoclonal antibodies are actually being thought-about for analysis.


Journal reference:

Pan, H., et al. (2020) Repurposed antiviral medication for COVID-19; interim WHO SOLIDARITY trial outcomes. BMJ.

Supply hyperlink

Leave a Reply